Long Huibin, Bai Wenjun, Zhang Xiaowei, Xu Tao
Department of Urology, Peking University People's Hospital, Beijing, China.
Department of Urology, Peking University People's Hospital, Beijing, China,
Urol Int. 2019;103(1):62-67. doi: 10.1159/000497281. Epub 2019 Mar 21.
Microsurgical denervation of the spermatic cord (MDSC) is a treatment option for chronic orchialgia (CO) refractory to conservative treatment. Studies showed specific nerve fibers as the possible cause of CO. We aimed to present the outcomes of ligation of these nerves using targeted MDSC.
We retrospectively reviewed 30 cases who underwent targeted MDSC from August 2014 to February 2018. Patients included were under strict criteria. Pain was assessed preoperatively and postoperatively using a subjective visual analog scale (VAS) and objectively with the standardized and validated Pain Impact Questionnaire-6 (PIQ-6) score.
Data were available on 28 cases at repercussion. During a median follow-up of 12 months (range 10-29), 25 cases (89.2%) showed a significant reduction in pain and 3 (9.8%) had no change in pain by subjective VAS scoring. Of cases with a significant reduction in pain, 15 (53.5%) had complete resolution and 19 (67.9%) had a 50% or greater reduction. Objective PIQ-6 analysis showed a significant reduction in pain in 78.6% of patients at 6 months postoperatively, in 82.1% at 1 year, in 82.1% at 2 years.
Targeted MDSC is an effective, minimally invasive approach with potential long-term durability in patients with refractory CO.
精索显微去神经术(MDSC)是一种针对保守治疗无效的慢性睾丸疼痛(CO)的治疗选择。研究表明特定神经纤维可能是CO的病因。我们旨在展示使用靶向MDSC结扎这些神经的效果。
我们回顾性分析了2014年8月至2018年2月期间接受靶向MDSC治疗的30例患者。纳入的患者符合严格标准。术前和术后使用主观视觉模拟量表(VAS)评估疼痛,并通过标准化且经过验证的疼痛影响问卷-6(PIQ-6)评分进行客观评估。
随访时有28例患者的数据可用。在中位随访12个月(范围10 - 29个月)期间,25例(89.2%)患者的疼痛通过主观VAS评分显著减轻,3例(9.8%)患者的疼痛无变化。在疼痛显著减轻的患者中,15例(53.5%)完全缓解,19例(67.9%)减轻了50%或更多。客观PIQ-6分析显示,术后6个月78.6%的患者疼痛显著减轻,1年时为82.1%,2年时为82.1%。
靶向MDSC是一种有效、微创的方法,对于难治性CO患者可能具有长期疗效。